₹-0.42
(Market cap
₹40 Cr
Recently Viewed
Clear AllMarket cap
₹40 Cr
Revenue (TTM)
₹64 Cr
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-44 Cr
ROE
-20.2 %
ROCE
-13.2 %
Industry P/E
34.01
EV/EBITDA
65.8
Debt to Equity
0.2
Book Value
₹10.7
EPS
₹-1.9
Face value
10
Shares outstanding
50,101,239
CFO
₹126.64 Cr
EBITDA
₹186.65 Cr
Net Profit
₹-36.60 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lasa Supergenerics
| -14.8 | 14.7 | -11.2 | -55.1 | -31.6 | -35.6 | -- |
|
BSE Healthcare
| 0.4 | 5.5 | 5.6 | 2.2 | 24.1 | 13.3 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lasa Supergenerics
| -64.7 | -10.7 | -11.1 | -50.9 | -18.8 | 354.8 | -43.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lasa Supergenerics
|
8.0 | 40.2 | 64.4 | -44.2 | -16.2 | -13.6 | -- | 0.7 |
| 1,050.1 | 12,891.6 | 2,512.3 | 543.7 | 28.3 | 19.3 | 23.7 | 4.1 | |
| 403.4 | 6,998.5 | 1,053.1 | 293.6 | 32.3 | 24.6 | 23.8 | 5.4 | |
| 1,016.2 | 10,627.4 | 1,158.7 | 309.6 | 31.9 | 17.3 | 34 | 5.6 | |
| 1,637.2 | 31,095.5 | 8,850.1 | 894.8 | 15.2 | 19.8 | 35.7 | 6.3 | |
| 359.9 | 3,925.5 | 159.3 | 47.8 | 39.0 | 18.6 | 82.1 | 14.2 | |
| 14,405.0 | 18,486.5 | 1,575.1 | 179.1 | 14.9 | 11.4 | 103.2 | 11.1 | |
| 891.2 | 4,100.6 | 588.5 | 102.9 | 22.1 | 12.7 | 40.4 | 4.8 | |
| 681.8 | 7,687.9 | 502.0 | 138.7 | -- | 32.8 | 55.4 | 8.9 | |
| 202.1 | 5,324.5 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.0 |
No Review & Analysis are available.
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole,... triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India. Read more
Incorporated
2016
Chairman
Omkar Pravin Herlekar
Managing Director
Omkar Pravin Herlekar
Headquarters
Ratnagiri Dist, Maharashtra
Website
Looking for more details about Lasa Supergenerics Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Lasa Supergenerics Ltd is ₹8.04 (NSE) and ₹8.03 (BSE) as of 24-Apr-2026 IST. Lasa Supergenerics Ltd has given a return of -31.58% in the last 3 years.
Since, TTM earnings of Lasa Supergenerics Ltd is negative, P/E ratio is not available.
The P/B ratio of Lasa Supergenerics Ltd is 0.75 times as on 24-Apr-2026, a 67 discount to its peers’ median range of 2.27 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
0.00
|
1.14
|
|
2023
|
0.00
|
0.78
|
|
2022
|
0.00
|
1.32
|
|
2021
|
10.70
|
1.53
|
|
2020
|
31.84
|
0.82
|
The 52-week high and low of Lasa Supergenerics Ltd are Rs 19.00 and Rs 5.67 as of 26-Apr-2026.
Lasa Supergenerics Ltd has a market capitalisation of ₹ 40 Cr as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Lasa Supergenerics Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.